Ivermectin, an FDA-approved antiparasitic drug derived from avermectin, has gained significant attention in oncology due to its potential antitumor effects observed in preclinical studies. Originally developed to treat parasitic infections such as river blindness and strongyloidiasis, it is now being explored for drug repositioning in cancer treatment. The interest stems from its ability to target multiple cancer pathways at doses that appear nontoxic to healthy cells, offering a potentially cost-effective adjunct to existing therapies. However, clinical evidence in humans remains limited, and experts strongly caution against self-medication, emphasizing the need for rigorous clinical trials.
This overview examines ivermectin’s effects on various tumor types, its mechanisms of action, ongoing clinical studies, research dosages, safety considerations, and some intriguing trivia. The discussion highlights the promise and limitations of this drug in oncology, urging caution until more robust data is available.
Effects on Different Tumor Types
Diverse Anticancer Activity
Ivermectin has shown promising antitumor effects across a range of cancers in preclinical studies, making it a versatile candidate for further research. In breast cancer, particularly triple-negative subtypes, it induces immunogenic cell death, transforming “cold” tumors into “hot” ones that are more responsive to immune checkpoint inhibitors like pembrolizumab. It also inhibits tumor growth and reverses drug resistance, enhancing treatment efficacy. Similarly, in colorectal cancer, ivermectin regulates cell cycle progression and promotes autophagy-mediated cell death through the AKT/mTOR pathway, showing activity even in resistant cell lines.
Impact on Aggressive Cancers
For aggressive cancers like glioblastoma, ivermectin suppresses angiogenesis and causes mitochondrial dysfunction, inhibiting tumor growth in both in vitro and in vivo models. In ovarian cancer, it targets cancer stem-like cells, reduces proliferation, and increases sensitivity to chemotherapy. Additionally, in leukemia, ivermectin promotes caspase-dependent apoptosis and autophagy, demonstrating efficacy across various blood cancer types. These findings, while primarily from cell lines and animal models, suggest broad potential, though clinical translation remains uncertain.
Other Tumor Types
Ivermectin also shows promise in cancers such as melanoma, hepatocellular carcinoma, pancreatic cancer, and esophageal cancer. In melanoma, it inhibits tumor stem cells and reverses multidrug resistance, potentially boosting other therapies. For hepatocellular carcinoma, it synergizes with drugs like sorafenib by targeting EGFR/ERK/AKT signaling. In pancreatic cancer, when combined with methioninase, it shows preclinical efficacy, while in esophageal cancer, it inhibits metastasis by targeting Yes-associated protein (YAP1). These diverse effects highlight ivermectin’s cross-species potential, but human data is still limited.
Mechanisms of Action
Multitargeting Tumor Pathways
Ivermectin’s anticancer effects arise from its ability to disrupt multiple tumor pathways, making it a potential enhancer for existing treatments. It inhibits proliferation, metastasis, and angiogenesis by targeting PAK1 kinase, a critical regulator of cell growth and spread. Additionally, it induces various forms of programmed cell death, including apoptosis via caspases, autophagy with cytostatic effects, pyroptosis, and immunogenic cell death, which enhances immune system recognition of tumors. These mechanisms allow ivermectin to attack cancer cells from multiple angles, increasing its therapeutic potential.
Overcoming Resistance and Enhancing Immunity
Another key mechanism is ivermectin’s ability to reverse drug resistance by targeting tumor stem cells and P-glycoprotein, a protein associated with chemotherapy resistance. This makes it a valuable adjunct to standard treatments, potentially improving outcomes in resistant cancers. Furthermore, ivermectin causes mitochondrial dysfunction and oxidative stress in cancer cells while synergizing with immunotherapies to boost T-cell infiltration. These properties position ivermectin as a multifaceted agent, though its clinical utility awaits confirmation through further studies.
Clinical Studies and Current Status
Early-Phase Trials
As of September 2025, clinical trials evaluating ivermectin in cancer treatment are primarily in early phases (Phase I/II), focusing on safety and combination therapies rather than standalone use. A notable example is a Phase II trial (Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer) investigating ivermectin combined with pembrolizumab or balstilimab for triple-negative breast cancer, assessing safety and preliminary efficacy. These trials aim to establish optimal dosing and identify synergistic effects with existing therapies. However, no large-scale Phase III trials have yet confirmed ivermectin’s efficacy in cancer, underscoring the need for further research.
Public Interest and Caution
Public interest in ivermectin’s anticancer potential has surged, often outpacing the available evidence and leading to unproven claims. Oncologists emphasize that while preclinical data is encouraging, myths and misinformation have spread rapidly, particularly following its controversial use during the COVID-19 era. Experts urge patients to participate in clinical trials rather than pursuing unproven off-label use, as the benefits in humans remain unestablished. Rigorous trials are essential to determine whether ivermectin can transition from a promising concept to a clinically viable treatment.
Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations
Dosage in Research Contexts
Experimental Dosing
In cancer research, ivermectin dosages are experimental and not standardized for clinical treatment. Its approved antiparasitic use is typically prescribed in a range from 150-200 mcg/kg as a single oral dose. Preclinical cancer studies have employed concentrations of 2-10 μM used in cell lines, while clinical trials explore oral doses of 200-400 mcg/kg daily or in cycles (e.g., 21 days). Higher doses, up to 1-2 mg/kg, have been tested for safety in repositioning studies but are not recommended outside controlled settings due to potential risks.
Risks of Self-Dosing
Self-dosing with ivermectin for cancer is strongly discouraged, as experimental doses may lead to overdose or adverse effects. Patients must consult oncologists before considering off-label use, as safe and effective dosages for cancer treatment are not yet established. The variability in research dosing highlights the importance of clinical oversight to prevent harm while exploring ivermectin’s potential.
Ivermectin Side Effects and Safety Considerations
Established Safety Profile
At approved antiparasitic doses, ivermectin has a well-established safety profile, with over 4 billion doses administered globally through programs like the Mectizan Donation Program. Common side effects include nausea, vomiting, diarrhea, dizziness, low blood pressure, itching, and allergic reactions, which are generally mild. In cancer trials, side effects remain mild to moderate, but high doses carry risks of severe effects such as seizures, coma, or organ dysfunction. Its selectivity for cancer cells is promising, but drug interactions with chemotherapy or other treatments require careful monitoring.
Precautions and Warnings
Ivermectin is not recommended for pregnant individuals or those with liver conditions, as these groups may face heightened risks. Experts caution that the unproven benefits of ivermectin in cancer do not outweigh the risks of self-medication, particularly in vulnerable patients. Participation in clinical trials under medical supervision is the safest way to explore its potential. Ongoing research aims to clarify its safety in oncology, but until then, caution is paramount.
Conclusion
Ivermectin’s potential as an anticancer agent is an exciting frontier, driven by its ability to target diverse tumor types through multiple mechanisms. Preclinical studies demonstrate robust effects, but clinical evidence remains in its infancy, with early-phase trials still evaluating safety and efficacy. Patients should avoid off-label use and consult oncologists, as self-medication carries significant risks. Continued research will determine whether ivermectin can become a viable adjunct in cancer therapy.
Trivia
Nobel Prize and Global Impact
Discovered in 1975 by Satoshi Ōmura and William C. Campbell, ivermectin earned them the 2015 Nobel Prize in Physiology or Medicine for its impact on parasitic diseases. Nicknamed the “wonder drug,” it has nearly eliminated river blindness in many regions through the Mectizan Donation Program. Its origins in soil bacteria from Japan highlight nature’s role in medical breakthroughs.
Veterinary Roots and Controversy
Initially developed as a veterinary drug, ivermectin’s safety profile allowed its widespread use in humans. However, its notoriety grew during the COVID-19 pandemic due to unproven claims, underscoring the need for evidence-based use. Despite this, its long history and versatility continue to fuel interest in its potential applications, including in oncology.
